Ketorolac Should Be Avoided in Elderly Patients with CKD and Hypertension
No, it is not safe to give ketorolac to elderly patients with CKD, even with normal serum creatinine and controlled hypertension. The FDA drug label explicitly contraindicates ketorolac in patients with impaired renal function, and multiple guidelines specifically recommend against NSAIDs in this population 1.
Why Normal Creatinine is Misleading in the Elderly
The critical pitfall here is that normal serum creatinine does not equal normal kidney function in elderly patients. Serum creatinine is a byproduct of muscle mass breakdown, and elderly patients have reduced muscle mass. This means they can have significantly impaired GFR (glomerular filtration rate) while maintaining "normal" laboratory creatinine values 2. The evidence shows that 26% of persons over 70 years have CKD despite potentially normal creatinine levels 2.
Direct Evidence Against Ketorolac Use
FDA Drug Label Warnings
The FDA label is unequivocal 1:
- Ketorolac is contraindicated in patients with serum creatinine concentrations indicating advanced renal impairment
- Must be used with extreme caution in patients with impaired renal function or history of kidney disease
- Patients with underlying renal insufficiency are at increased risk of acute renal decompensation or failure
- NSAIDs can worsen preexisting hypertension and contribute to cardiovascular events
- Elderly patients require dose adjustment or the medication should be avoided altogether
Guideline Recommendations
The 2024 KDIGO guidelines explicitly state that for acute gout treatment in CKD, low-dose colchicine or glucocorticoids are preferable to NSAIDs 3. This reflects the broader principle that NSAIDs should be avoided in CKD patients.
The Hypertension Factor Compounds Risk
NSAIDs, including ketorolac, can:
- Lead to new-onset hypertension or worsen preexisting hypertension 1
- Impair response to thiazide or loop diuretics 1
- Cause fluid retention, edema, and sodium retention 1
- Increase cardiovascular thrombotic event risk 1
Blood pressure must be monitored closely during NSAID treatment, but the safer approach is simply to avoid the drug in this high-risk population 1.
Recent Research Shows Mixed but Concerning Results
While some recent surgical studies suggest single low-dose ketorolac (30 mg) may not increase AKI risk in patients without CKD 4, 5, a 2025 study specifically found that ketorolac in patients with CKD increased AKI incidence from 2.0% to 12.7% 6. This represents a more than 6-fold increase in risk.
The older case reports from the 1990s document acute renal failure in elderly patients receiving ketorolac, emphasizing that risk factors include advanced age, volume depletion, and preexisting mild renal dysfunction 7, 8.
Practical Algorithm for Decision-Making
For elderly patients with CKD and hypertension:
- Calculate actual GFR using Cockcroft-Gault or CKD-EPI equations—do not rely on serum creatinine alone
- If GFR <60 mL/min: Absolutely avoid ketorolac
- If GFR 60-90 mL/min with hypertension: Still avoid—use alternative analgesics
- Alternative pain management options:
- Acetaminophen (first-line for mild-moderate pain)
- Low-dose opioids for short-term use if needed
- Regional anesthesia techniques when applicable
- Gabapentinoids for neuropathic components
Key Clinical Pitfalls to Avoid
- Don't be fooled by "normal" creatinine in elderly patients—always calculate GFR
- Don't assume short-term use is safe—even single doses have caused AKI in high-risk patients 8
- Don't overlook volume status—dehydration dramatically increases NSAID nephrotoxicity risk 7
- Don't forget drug interactions—concurrent ACE inhibitors, ARBs, or diuretics further increase risk
The convergence of elderly age, CKD (even if mild), and hypertension creates a perfect storm for NSAID-induced complications. The risk-benefit ratio strongly favors avoiding ketorolac entirely in this population 1, 6.